* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download (Ureaplasma) in the Newborn
Meningococcal disease wikipedia , lookup
Hepatitis C wikipedia , lookup
Hepatitis B wikipedia , lookup
Onchocerciasis wikipedia , lookup
Eradication of infectious diseases wikipedia , lookup
Leptospirosis wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
Sexually transmitted infection wikipedia , lookup
Dirofilaria immitis wikipedia , lookup
Middle East respiratory syndrome wikipedia , lookup
Chagas disease wikipedia , lookup
Neisseria meningitidis wikipedia , lookup
Schistosomiasis wikipedia , lookup
Mycoplasma pneumoniae wikipedia , lookup
Oesophagostomum wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Visceral leishmaniasis wikipedia , lookup
Genital Mycoplasmal Disease in the Newborn John Baier M.D. University of Manitoba Characteristics of Mycoplasmas Mycoplasmas are the smallest self replicating organisms Do not have a cell wall like other bacteria • Do not Gram stain Small genome and lack enzymes needed to synthesize may compounds • • • • Complex nutritional requirements Require host cells and their products Difficult to culture outside of hosts Will not grow on routine bacteriologic media Mycoplasmas in Human Disease Difficulties in culturing have made establishing a pathogenic role of mycoplasmas difficult Diseases caused by mycoplasmas • acute Mycoplasma pneumoniae • often subacute or chronic • lack well defined clinical presentations Mycoplasmas in Human Disease Diseases potentially caused by mycoplasmas • Periodontal disease • Arthritis • Urethritis, cervicitis • Prematurity • Recurrent pregnancy loss • AIDS related diseases • Chronic lung disease Mycoplasma salivarium Mycoplasma arthitidis, Mycoplasma fermentans Mycoplasma hominis, Ureaplasma urealyticum Mycoplasma hominis, Ureaplasma urealyticum Mycoplasma hominis, Ureaplasma urealyticum Mycoplasma penetrans, Mycoplasma fermentans Mycoplasma hominis, Ureaplasma urealyticum Mycoplasmas Colonizing the Genital Tract Ureaplasma urealyticum/ Ureaplasma parvum • • • • Mycoplasma hominis • • • • premature labor pneumonia meningitis BPD premature labor pneumonia meningitis BPD? Mycoplasma fermentans • no known association with perinatal disease Mycoplasma genitalium • Only detectable by PCR • no known association with perinatal disease Epidemiology of Genital Tract Mycoplasmas Commonly found • 40-80% pregnancies colonized with Ureaplasma urealyticum • 5-50% pregnancies colonized with Mycoplasma hominis Increased colonization with • increased number of sexual partners • earlier age of first intercourse • isolation of other STDs (Chlamydia trachomatis) Transmission of Ureaplasma urealyticum to the Newborn Vertical transmission • 18-55% in term infants • 29-55% in preterm infants Factors that increase chance of transmission to fetus • rupture of membranes • chorioamnionitis • vaginal delivery Transmission rate varies with gestational age Once acquired colonization of respiratory tract may persist for months untreated Percent Transmission Perinatal Transmission of Ureaplasma to Newborn 100 90 80 70 60 50 40 30 20 10 0 <1500 1501- 2001- 2501- 3001- 3001- >3500 2000 2500 3000 3500 3500 Klein JO 1969 Birth Weight Consequences of Genital Mycoplasma Infections in the Newborn Variable response to infection • self limited with no long term effects • acute pneumonia • chronic inflammatory response may lead to development of chronic lung disease Ureaplasma urealyticum as a cofactor in the development of BPD BPD is a multifactorial disease • Uu is not THE CAUSE of BPD Conflicting data in the literature • different culture sites/methods – single culture vs. multiple culture – tracheal aspirate vs. nasal aspirate – reliability of cultures – PCR vs. culture • different populations – not a disease of larger infants • colonization with Uu is of no significance (generally) in a otherwise healthy term infant – different frequencies of organisms causing preterm birth Overall, isolation of Uu from airways is associated with a 2-3 fold increase in the incidence of oxygen dependency at 28 days of age Associated with a lesser but still significant increase in the incidence of oxygen dependency at 36 weeks PCA Percent BPD Ureaplasma urealyticum as a cofactor in the development of BPD 100 90 80 70 60 50 40 30 20 10 0 * LSU 1992-94 *p<0.001 Uu present Uu absent Mechanisms of lung injury caused by Mycoplasmas Live and heat killed mycoplasmas induce inflammatory cytokine production in a variety of lung cell types • mononuclear cells (alveolar macrophages) • respiratory epithelium • fibroblasts In most mycoplasmas the cytokine inducing activity is been determined to be membrane lipoproteins • slight similarity to LPS • utilize LPS receptors (toll like receptors) The component that stimulates cytokine production has not been determined for Ureaplasma urealyticum In vitro infection with U. urealyticum preterm monocyte cytokine release Monocytes from preterm cord blood (24 to 32 weeks) were incubated with CRPMI-10% FCS alone, U. urealyticum at 103 CCU (UU3) (low inoculum) or 106 CCU (UU6) (high inoculum), or LPS (100 ng/ml) with or without U. urealyticum for 24 h. (A) TNF- ; (B) IL-6; (C) IL-10; (D) IL-8. Results are expressed as percentages of the LPS positive control value n = 6). *, P < 0.05 versus medium control; P < 0.05 versus LPS. , Pulmonary Inflammation and isolation of Ureaplasma urealyticum MCP-1 pg/ug Sec 3000 No Uu Uu 2500 2000 1500 1000 500 0 1 3 5 9 Age (Days) 14 21 Induction of CC chemokines by M hominis and U urealyticum: Cord blood mononuclear cells Cytokine (pg/ml) 8000 7000 6000 5000 MIP-1 alpha MIP-1 beta MCP-1 MCP-2 MCP-3 4000 3000 2000 1000 0 Control Uu Control Mh Uu increases inflammatory responses in animal models Yoder et al 2003 • Intra-amniotically infected premature baboons • Increased inflammatory cell infiltrate in Uu +ve animals compared to controls of Uu – ve animals • Predominately monocytic cells Factors determining “pathogenicity” of Genital Mycoplasmas Gestational age • animal models suggest that immature animals develop more severe disease • clinically this is a disease of the smallest infants – reduced transfer of maternal IgG – immature immune responses Surfactant deficiency • infants with mature lungs rarely develop problems • lack of mycoplasmacidal effects of surfactant proteins Oxygen administration/Mechanical ventilation • synergistic effect between oxygen and infection Maternal immune response • low antibody production in mother increases risk of disease in newborn Genetic Factors? • Variations in cytokine or pathogen pattern recognition genes – IL-1RA (maternal) – TLR2 Biovar or serotype does not play a role • no specific pathogenicity factor known Surfactant protein A: mediation of mycoplasmacidal activity of alveolar macrophages Hickman-Davis et al 1998 Clinical Presentation Transient colonization Non resolving HMD/Persistent colonization Rapid development of BPD like changes Pneumonia PPHN (rare) Apnea Transient respiratory tract colonization Incidence is not known May constitute ~ 25% of culture positive infants Present with mild-moderate respiratory distress • HMD or TTN • Positive culture for Uu/Mh incidental Rapid resolution without sequelae Culture results return after patient is extubated and relatively well Require no treatment Non resolving HMD/Persistent colonization Represents largest proportion of infants Initial presentation of typical HMD Incomplete resolution May have multiple cultures positive • initial may be negative Infants with persistent Uu are more likely to develop BPD Outcome (percent) 100 O2 at 28 days O2 at 36 weeks 80 60 40 20 0 Follow up Uu culture negative or indeterminate Baier RJ et al 2003 Follow up Uu culture positive Rapid development of BPD like changes Initial presentation of typical HMD • does not have to be severe Poor resolution Development of cystic appearance by first weeks of life • can be confused with PIE • likely represents pneumonia Worse prognosis? Ureaplasmal pneumonia May present at birth • indistinguishable from HMD • pneumonic appearance May present several weeks after birth • apnea • respiratory distress • may progress to chronic lung disease No other agent is cultured Adverse CNS Outcomes in infants with Ureaplasma urealyticum 70 * Uu Positive 60 Uu Negative * Incidence (%) 50 * 40 30 20 10 0 All IVH Severe IVH Hydrocephalus Shunt *p<0.02 Incidence (%) Interaction between isolation of Uu and IL-1b –511T polymorphism 45 40 35 30 25 20 15 10 5 0 IVH Uu negative and 511T negative Uu Positive and 511T neagtive PVL IVH or PVL Uu negative and 511T positive Uu Positive and 511T positive Diagnosis and Management of Mycoplasmal Infections Diagnosis of Genital Mycoplasma infections Who to culture? • Routine – Infants with birth weight less than 1500 grams – mechanical ventilation – preterm labor ± ROM, chorioamnionitis • Suspect genital mycoplasmas – early BPD like changes – non resolution of HMD – culture negative pneumonia Diagnosis of Genital Mycoplasma infections What to culture? • Tracheal aspirate • Blood ? • Little predictive value of positive cultures from nose, throat, rectum, gastric aspirate Value of repeated cultures? • Persistent positive cultures correlate better with development of BPD • frequently initial culture at birth may be negative • 3x during first week if intubated Diagnosis of Genital Mycoplasmas Culture methods • Mycoplasmas are not hardy organisms – fresh specimens • specialized transport media – frozen – blood – CSF • frequently there are natural inhibitors to growth – serial dilutions – multiple media • cultures are difficult to interpret – require microscopic examination of colony formation – color change in media may be from other organisms Diagnosis of Genital Mycoplasmas Polymerase Chain Reaction (PCR) Ureaplasma • Urease gene • Multiple banded antigen – distinguishes between U. urelyticum and U. parvum Mycoplasma hominis • 16S rRNA gene PCR for Ureaplasma based on Urease gene PCR vs Culture PCR • rapid results <24 hours • biovar information • very sensitive – relevance of detecting ~ 10 organisms Culture • may take longer than a week for positive ID • no biovar information • false negatives may be common depending on lab experience and specimen handling • less sensitive – detects larger numbers of viable organisms Treatment Strategies Should Whom What you treat to treat? to treat with? Treatment of Genital Mycoplasmas Treatment of genital mycoplasmas is controversial No studies have been done to show that it alters outcome • diagnosis and treatment is often delayed – not considered – cultures take 5-7 days • distinguishing between colonization and infection • strains of Ureaplasma may be resistant to antimicrobials Treatment of Genital Mycoplasmas: Strategies Empiric treatment of at risk infants • no studies • possible benefit of early treatment • treatment of infants who won’t develop disease with broad spectrum antibiotics – increased risk to develop yeast infections? Treatment of culture positive or persistently positive infants • delay of treatment after much of the damage may be done • the few studies done show little or no benefit Treatment of Genital Mycoplasmas Ureaplasma urealyticum • sensitive to macrolide antibiotics • erythromycin 30-40 mg/kg/day – 10-14 days (no studies) – Failure to clear organism • azithromycin – no data – 10mg/kg day 1 then 5/mg/kg/day x 6days? • insensitive to clindamycin • sensitive to chloramphenicol and tetracyclines – resistant cases or meningitis? 100 Positive TA culture (%) 80 60 40 20 0 Day 0 Day 5 Day 10 Day 15 Time after start of treatment (days) Baier RJ et al 2003 Treatment of Genital Mycoplasmas Mycoplasma hominis • • • • insensitive to macrolides may be sensitive to gentamicin (not reliable) sensitive to clindamycin sensitive to chloramphenicol and tetracyclines – resistant cases or meningitis? Summary Genital mycoplasmas frequently colonize and infect the respiratory tract of preterm infants Infants may develop self limited disease from infection or may have chronic inflammation that may predispose to the development of BPD Identification and treatment of infants with these organisms is frequently delayed or missed because of specialized culture requirements The benefits of treating these infants have not been determined although treatment of infants with pneumonia or chronic inflammation may be warranted